¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"T cell antigen receptors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • cell lethality
    ¼¼Æ÷Ä¡»çÀ²
  • cell line
    ¼¼Æ÷ÁÖ, ¼¼Æ÷°è
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • cell mass
    ¼¼Æ÷µ¢ÀÌ, ¼¼Æ÷±«
  • cell membrane
    ¼¼Æ÷¸·
  • cell membrane permeability
    ¼¼Æ÷¸·Åõ°ú¼º
  • cell organelle
    ¼¼Æ÷¼Ò±â°ü
  • cell respiration
    ¼¼Æ÷È£Èí
  • cell strain
    ¼¼Æ÷ÁÖ
  • cell substitution
    ¼¼Æ÷´ëü, Ç÷±¸´ëü
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cell swelling
    ¼¼Æ÷Á¾Ã¢
  • cell-associated antibody
    ¼¼Æ÷¿¬°üÇ×ü
  • cell-bound antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • cell labeling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
  • cell membrane permeability
    ¼¼Æ÷¸·Åõ°ú¼º
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cell-associated virus
    ¼¼Æ÷ºÎÂø¹ÙÀÌ·¯½º
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity
    ¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¸Å°³¸é¿ª°áÇÌÁõÈıº
  • cell-mediated lympholysis test
    ¼¼Æ÷¸Å°³¸²ÇÁ±¸¿ëÇØ½ÃÇè
  • centroacinar cell
    »ù²Ê¸®Á߽ɼ¼Æ÷
  • chief cell
    À¸¶ä¼¼Æ÷
  • Chinese hamster ovary cell
    Áß±¹ºñ´ÜÅÐÁã³­¼Ò¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • antigen, public
    ÀϹÝÇ׿ø, °øÅëÇ׿øcf.private antigen
  • antigen, self
    ÀÚ°¡Ç׿ø, ÀÚ±âÇ׿ø
  • antigen, sequestered
    °Ý¸®Ç׿ø
  • antigen, serologically defined
    Ç÷ûÇÐÀû ±ÔÁ¤Ç׿ø, SDÇ׿ø
  • antigen, soluble
    ¼ö¿ë¼ºÇ׿ø
  • antigen, somatic
    ü¼¼Æ÷Ç׿ø
  • antigen, species-specific
    Á¾Æ¯ÀÌÇ׿ø
  • antigen, theta
    ¼¼Å¸¥èÇ׿ø
  • antigen, thymus-dependent
    Èä¼±ÀÇÁ¸Ç׿ø, °¡½¿»ùÀÇÁ¸Ç׿ø
  • antigen, thymus-independent
    Èä¼±ºñÀÇÁ¸Ç׿ø, °¡½¿»ùºñÀÇÁ¸Ç׿ø
  • antigen, thymus-leukemia
    Èä¼±-¹éÇ÷º´Ç׿ø, TLÇ׿ø
  • antigen, transplantation
    À̽ÄÇ׿ø
  • antigen, tumor-specific
    Á¾¾çƯÀÌÇ׿ø
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,carcinoembryonic
    ¾ÏÁ¾¹è¾Æ¼º(äßðþÛÏä´àõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • early antigen
    ÃʱâÇ׿ø
  • envelope antigen
    ¿ÜÇÇÇ׿ø.
  • environmental antigen
    ȯ°æÇ׿ø
  • erythrocyte antigen
    ÀûÇ÷±¸Ç׿ø
  • erythrocyte antigen test
    ÀûÇ÷±¸Ç׿ø½ÃÇè
  • excess zone, antigen
    Ç׿ø°úÀ׿ª
  • extractable nuclear antigen
    ÃßÃâ°¡´ÉÇÙÇ׿ø
  • extractable nuclear antigen
    ÃßÃâ°¡´ÉÇÙ Ç׿ø
  • factor VIII coagulant antigen
    Á¦ VIII ÀÎÀÚÀÀ°íÇ׿ø
  • factor VIII-related antigen
    Á¦ VIII-°ü·ÃÇ׿ø
  • fetal antigen
    ÅÂ¾Æ Ç׿ø(¡­ù÷ê«)
  • fetal tumor-associated antigen
    ÅÂ¾Æ Á¾¾ç °ü·Ã Ç׿ø
  • fimbrial antigen
    ¼¶¸ðÇ׿ø(àéÙ¾ù÷ê«).
  • flagellar antigen
    Æí¸ðÇ׿ø(ø½Ù¾ù÷ê«).
  • formalinized antigen
    Æ÷¸£¸»¸°È­Ç׿ø.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • Olfactory cell
    Èİ¢¼¼Æ÷
    [¿¾ ¿ë¾î] Èİ¢¼¼Æ÷
  • Spinous cell
    °¡½Ã¼¼Æ÷
    [¿¾ ¿ë¾î] À¯±Ø¼¼Æ÷
  • Dendriform cell
    ³ª¹µ°¡Áö¼¼Æ÷
    [¿¾ ¿ë¾î] ¼öÁö»ó¼¼Æ÷
  • Endocrine cell
    ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ºÐºñ¼¼Æ÷
  • Colliculiform cell
    µÐ´ö¼¼Æ÷
    [¿¾ ¿ë¾î] ¼Ò±¸¼¼Æ÷
  • Microvillous cell
    ¹Ì¼¼À¶¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ¹Ì¼¼À¶¸ð¼¼Æ÷
  • Smooth muscle cell
    ¹Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] ÆòȰ±Ù±Ù¼¼Æ÷
  • Light cell
    ¹àÀº¼¼Æ÷
    [¿¾ ¿ë¾î] ¸í¼¼Æ÷
  • Light cell
    ¹àÀº¼¼Æ÷
    [¿¾ ¿ë¾î] ¸íÁÖ¼¼Æ÷
  • Fusiform cell
    ¹æÃß¼¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃ߻󼼯÷
  • Supporting cell
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Cell of reticulum
    ¹úÁýÀ§Ä­
    [¿¾ ¿ë¾î] ¼¼¸Á¼¼Æ÷
  • Kupffer`s cell
    º°Å«Æ÷½Ä¼¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó¼¼¸Á³»ÇǼ¼Æ÷
  • Mitotic cell
    ºÐ¿­±â¼¼Æ÷
    [¿¾ ¿ë¾î] ºÐ¿­±â¼¼Æ÷
  • Intermitotic cell
    ºÐ¿­»çÀ̱⼼Æ÷
    [¿¾ ¿ë¾î] °£±â¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
MCSA Moloney cell surface antigen
PCNA proliferating cell nuclear antigen
SLA left sacroanterior [fetal position] [Lat. sacrolaeva anterior]; single-cell liquid cytotoxic assay; ...
TALLA T-cell acute lymphoblastic leukemia antigen
TCAR T-cell antigen receptor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
PCNA LI proliferating cell nuclear antigen labeling index
SCC squamous cell carcinoma related antigen
ES cell embryonic stem cell
LAK cell lymphokine activated killer cell
M cell Mauthner cell
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • columnar epithelial cell
    ¿øÁÖ »óÇÇ ¼¼Æ÷
  • columns of cartilage cell
    ¿¬°ñ ¼¼Æ÷ ±âµÕ, ¿¬°ñ ¼¼Æ÷ÁÖ
  • committed cell
    À§Å¹ ¼¼Æ÷
    ¾î¶² ƯÁ¤ÇÑ Ç׿ø °áÁ¤±º¿¡ ´ëÇØ¼­ ƯÀÌÀûÀÎ Ç×ü¸¦ »ý»êÇϵµ·Ï À§Å¹µÈ ¼¼Æ÷. À§Å¹ ¼¼Æ÷¿¡´Â Ç׿øÀÌ Á¢Ã˵Ǿú´ø ÀûÀÌ ÀÖ´Â ¼¼Æ÷, ±â¾ï¼¼Æ÷, ¹× Ç×ü»ý»ê ¼¼Æ÷ µîÀÌ Æ÷ÇԵȴÙ.
  • companion cell
    µ¿¹Ý ¼¼Æ÷
  • cone cell
    ¿ø»Ô ¼¼Æ÷, Ãß»óü ¼¼Æ÷, ¿øÃß ¼¼Æ÷
    ôÃßµ¿¹°ÀÇ ¸Á¸·ÀÇ °¡Àå ¾ÈÂÊ¿¡ ÀÖ´Â ½Ã¼¼Æ÷ÀÇ ÀÏÁ¾. Ãßü ¼¼Æ÷, Ãß»óü ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. ½Ã¼¼Æ÷´Â ±× ÇüÅÂ¿Í ±â´É»ó¿¡ µû¶ó ¿øÃß ¼¼Æ÷¿Í °£»ó ¼¼Æ÷ÀÇ 2Á¾À¸·Î ±¸º°µÈ´Ù. ¿øÃß ¼¼Æ÷´Â ºñ±³Àû ¹àÀº °÷¿¡¼­ ¹°Ã¼¸¦ º¸´Â ÀÏ, »öÀ» ½Äº°
  • congenital granular cell epulis
    ¼±ÃµÀû °ú¸³¼¼Æ÷¼º Ä¡ÀºÁ¾
  • cornified epithelial cell
    °¢È­ »óÇÇ ¼¼Æ÷
  • cortical cell
    ÇÇÁú ¼¼Æ÷
  • crystal cell
    °áÁ¤ ¼¼Æ÷
    ³»ºÎ¿¡ °¢Á¾ °áÁ¤À» ÇÔÀ¯ÇÏ´Â ¼¼Æ÷. ºÐºñ ¼¼Æ÷ÀÇ ÀÏÁ¾À¸·Î, º¸Åë ÁÖÀ§ÀÇ ¼¼Æ÷¿Í ¸ð¾çÀÌ ¾à°£ ´Ù¸£´Ù. Á¤¹æÁ¤°è ¶Ç´Â ´Ü»çÁ¤°è·Î µÈ Å« ¿Á»ì»ê Ä®½· °áÁ¤À» º£°í´Ï¾Æ¼Ó µî ½Ä¹°Á¶Á÷ ³»¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Ù. ¶§·Î´Â ¼ÒÇüÀÇ °áÁ¤ÀÌ ´Ù¼ö ±ºÁýÇÏ¿© °áÁ¤»ç°¡ µÇ°Å³ª ħ»ó °áÁ¤ÀÌ ´Ù¼ö ÆòÇàÀ¸·Î ¹è¿­µÇ¾î °áÁ¤ ¼ÓÀÌ µÈ´Ù
  • cutaneous B cell lymphoma
    ÇǺΠB ¼¼Æ÷ ¸²ÇÁÁ¾
  • cylindrical cell
    ¿øÁÖÇü ¼¼Æ÷, ¿øÁÖ»ó ¼¼Æ÷
  • daughter cell
    µþ ¼¼Æ÷, ³¶ ¼¼Æ÷
    1. ¸ð¼¼Æ÷°¡ ºÐ¿­ÇÏ¿© »ý±â´Â ¼¼Æ÷. 2. ¼¼Æ÷ ºÐ¿­ÀÇ °á°ú·Î »ý±ä 2°³ÀÇ »õ·Î¿î ¼¼Æ÷. ºÐ¿­ ÀüÀÇ ¸ð¼¼Æ÷¿¡ ´ëÇØ¼­ µþ ¼¼Æ÷¶ó°í ÇÏ¸ç ³¶ ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. µþ ¼¼Æ÷ÀÇ ÇÙÀº 2°³°¡ ¼­·Î ³»¿ëÀÌ °°À¸¸ç, ¶Ç ¸ð¼¼Æ÷ÀÇ ÇÙ°úµµ ¶È°°Àºµ¥ ¼¼Æ÷ÁúÀº ¾à°£ ´Ù¸£´Ù. °¨¼öºÐ¿­ÀÇ Á¦1ºÐ¿­¿¡ ÀÇÇÏ¿© »ý±â´Â 2°³ÀÇ µþ¼¼Æ÷ÀÇ ¿°»öü ¼ö´Â ¸ð¼¼Æ÷ÀÇ ¹Ý¼ö·Î µÇ¾î ÀÖ´Â °ÍÀÌ º¸ÅëÀÌ´Ù.
  • Deiters cell
    ´ÙÀÌÅ׸£½º ¼¼Æ÷
    ³»ÀÌÀÇ ´ÞÆØÀ̰ü ³»ÀÇ ±âÀú¸· À§¿¡ ÀÖ´Â ÄÚ¸£Æ¼±â¸¦ ±¸¼ºÇÏ´Â ÀÏÁ¾ÀÇ ¼¼Æ÷. Á÷Á¢ ¼Ò¸® °¨°¢À» ¹Þ´Â ¿ÜÀ¯¸ð¼¼Æ÷ °£±ØÀ» ä¿ì°í ÀÖ´Â ÁöÁö¼¼Æ÷.
  • delta cell tumor
    µ¨Å¸ ¼¼Æ÷ Á¾¾ç
    ¼Ò¸¶Å佺ŸƾÀ» ºÐºñÇÏ´Â Á¾¾çÀ¸·Î ¼Ò¸¶Å佺ŸƾÁ¾
  • diploid cell
    2¹èü ¼¼Æ÷
    Á¤»óÀÇ 2¹è¼ºÀÇ ¿°»öü, ¶Ç´Â 2°³ÀÇ ÇÙÀ» °¡Áø ¼¼Æ÷. Á¤»óÀÎ Á¶Á÷ ¾È¿¡¼­´Â ¼öÁ¤¶õÀ̳ª ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ º¼ ¼ö ÀÖ´Ù. ÀΰøÀûÀ¸·Î´Â HVJ³ª NDA µîÀÇ ¹ÙÀÌ·¯½º³ª
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
receptors, adrenergic, beta One of the two major pharmacologically defined classes of adrenergic receptors. The alpha-beta distinction was originally based on the cellular effects of receptor activation but now relies on the relative affinities for characteristic synthetic ligands. Beta adrenergic receptors are further subdivided based on information from endogenous and cloned receptors.
(12 Dec 1998)
receptors, adrenergic, beta-1 A subclass of beta-adrenergic receptors (receptors, adrenergic, beta). Beta-1 adrenergic receptors are equally sensitive to epinephrine and norepinephrine and bind the agonist dobutamine and the antagonist metoprolol with high affinity. They are found in the heart, juxtaglomerular cells, and in the central and peripheral nervous systems.
(12 Dec 1998)
receptors, adrenergic, beta-2 A subclass of beta-adrenergic receptors (receptors, adrenergic, beta). Beta-2 adrenergic receptors are more sensitive to epinephrine than to norepinephrine and have a high affinity for the agonist terbutaline. They are widespread, with clinically important roles in skeletal muscle, liver, and vascular, bronchial, gastrointestinal, and genitourinary smooth muscle.
(12 Dec 1998)
receptors, albumin Cell surface proteins that bind albumin with high affinity and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, aldosterone Cytoplasmic proteins that specifically bind aldosterone and mediate its cellular effects. The aldosterone-bound receptor acts in the nucleus to regulate the transcription of specific segments of DNA.
(12 Dec 1998)
receptors, amino acid Cell surface proteins that bind amino acids and trigger changes which influence the behaviour of cells. Glutamate receptors are the most common receptors for fast excitatory synaptic transmission in the vertebrate central nervous system, and gaba and glycine receptors are the most common receptors for fast inhibition.
(12 Dec 1998)
receptors, ampa Cell surface proteins that bind glutamate and directly gate ion channels in cell membranes. Ampa receptors were originally discriminated from other glutamate receptors by their affinity for the agonist ampa (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid). They are probably the most common mediators of fast excitatory synaptic transmission in the central nervous system. Several subtypes have been cloned, and for some types the traditional distinction from kainate receptors may not apply.
(12 Dec 1998)
receptors, androgen Proteins, generally found in the cytoplasm, that specifically bind androgens and mediate their cellular actions. The complex of the androgen and receptor migrates to the nucleus where it induces transcription of specific segments of DNA.
(12 Dec 1998)
receptors, angiotensin Cell surface proteins that bind angiotensins and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, aryl hydrocarbon Cytoplasmic proteins that bind certain aryl hydrocarbons, translocate to the nucleus, and activate transcription of particular DNA segments. Ah receptors are identified by their high-affinity binding to several carcinogenic or teratogenic environmental chemicals including polycyclic aromatic hydrocarbons found in cigarette smoke and smog, heterocyclic amines found in cooked foods, and halogenated hydrocarbons including dioxins and polychlorinated biphenyls. No endogenous ligand has been identified, but an unknown natural messenger with a role in cell differentiation and development is suspected.
(12 Dec 1998)
receptors, atrial natriuretic factor Cell surface proteins that bind atrial natriuretic factor with high affinity and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, biogenic amine Cell surface proteins that bind biogenic amines with high affinity and regulate intracellular signals which influence the behaviour of cells. Biogenic amine is a chemically imprecise term which, by convention, includes the catecholamines epinephrine, norepinephrine, and dopamine, the indoleamine serotonin, the imidazolamine histamine, and compounds closely related to each of these.
(12 Dec 1998)
receptors, bombesin Cell surface proteins that bind bombesin or closely related peptides with high affinity and trigger intracellular changes influencing the behaviour of cells. Gastrin- releasing peptide (grp), grp 18-27 (neuromedin c), and neuromedin b are endogenous ligands of bombesin receptors in mammals.
(12 Dec 1998)
receptors, bradykinin Cell surface receptors that bind bradykinin and related kinins with high affinity and trigger intracellular changes which influence the behaviour of cells. The identified receptor types (b-1 and b-2, or bk-1 and bk-2) recognise the endogenous kallidins, t-kinins, and certain bradykinin fragments as well as bradykinin itself.
(12 Dec 1998)
receptors, calcitonin Cell surface proteins that bind calcitonin and trigger intracellular changes which influence the behaviour of cells. Calcitonin receptors outside the nervous system mediate the role of calcitonin in calcium homeostasis. The role of calcitonin receptors in the brain is not well understood.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
ÅëÇÕ°Ë»ö ¿Ï·á